减少C.C.的使用. 困难相关疾病使用多方面的方法
Numair Damani1, Ruth Montgomery2, Stephen Wallace2
1The Malthouse Surgery, The Charter, Abingdon, UK.
Journal of infection prevention
|November 3, 2025
概括
困难菌感染 (CDI) 是一个主要的医疗威胁. 一个多方面的干预策略成功地在一年内将CDI发作减少了77%,证明了它在对抗这种感染方面的有效性.
科学领域:
- 传染性疾病 传染性疾病
- 医疗卫生流行病学 医疗卫生流行病学
- 公共卫生干预措施 公共卫生干预措施
背景情况:
- 困难菌是医院获得的腹的主要原因,导致严重的发病率和死亡率.
- 症状范围从轻微的腹到严重的伪膜性结肠炎和死亡.
- 2008年观察到克洛斯特里迪奥伊德困难感染 (CDI) 病例的增加.
研究的目的:
- 评估多面干预策略对减少CDI发作事件的影响.
- 评估医疗保健环境中干预的长期有效性.
主要方法:
- 南方卫生和社会护理信托基金 (SHSCT) 实施多方面的方法来打击CDI.
- 在干预实施之前和之后监测医院患者的CDI发作.
主要成果:
- 65岁以上患者的CDI发作在第一年内减少了77% (从2008-09年的164次减少到2009-10年的37次).
- 观察到CDI发作持续减少,到2021/2022年与2008/09年相比,CDI发作减少了64%.
- 这项干预措施导致医院获得的CDI显著下降.
结论:
- 多方面的干预策略对于降低医疗保健中获得的CDI的发生率至关重要.
- 这些策略的成功实施可以导致CDI利率大幅降低.
- 需要持续监测和干预,以保持低CDI发病率.
相关概念视频
Healthcare Associated Infections II: Preventive Measures
3.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.6K
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Peptic Ulcer Disease IV: Management
424
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
424
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615


